Review of the Clinical and Economic Burden of Antibody-Mediated Rejection in Renal Transplant Recipients.

about

Impact of complement component 3/4/5 single nucleotide polymorphisms on renal transplant recipients with antibody-mediated rejection.

P2860

Q49297064-1CC81561-D48B-4E50-A550-CBD53F47EE03

P2860

Review of the Clinical and Economic Burden of Antibody-Mediated Rejection in Renal Transplant Recipients.

Item

http://www.wikidata.org/entity/Q38746225

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Review of the Clinical and Eco ...... n Renal Transplant Recipients.

@en

type

Item

label

Review of the Clinical and Eco ...... n Renal Transplant Recipients.

@en

prefLabel

Review of the Clinical and Eco ...... n Renal Transplant Recipients.

@en

P1476

Review of the Clinical and Eco ...... n Renal Transplant Recipients.

@en

P2093

Gorden Muduma

http://www.w3.org/2001/XMLSchema#string

Isaac Odeyemi

http://www.w3.org/2001/XMLSchema#string

Jayne Smith-Palmer

http://www.w3.org/2001/XMLSchema#string

P2860

Treatment options and strategies for antibody mediated rejection after renal transplantation

Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria

Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection.

The role of proteasome inhibition with bortezomib in the treatment of antibody-mediated rejection after kidney-only or kidney-combined organ transplantation.

Eculizumab treatment of acute antibody-mediated rejection in renal transplantation: case reports.

Long-term outcome of anti-glomerular basement membrane antibody disease treated with immunoadsorption.

Mechanisms of action of antithymocyte globulin: T-cell depletion and beyond.

Diagnosis and management of antibody-mediated rejection: current status and novel approaches.

Retrospective chart review of severe infusion reactions with rituximab, cetuximab, and bevacizumab in community oncology practices: assessment of clinical consequences.

Banff 2011 Meeting report: new concepts in antibody-mediated rejection

P2888

s12325-016-0292-y

P304

345-356

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S12325-016-0292-Y

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Richard F Pollock

P577

2016-02-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1011998437

http://www.w3.org/2001/XMLSchema#string

P698

26905265

http://www.w3.org/2001/XMLSchema#string

Review of the Clinical and Economic Burden of Antibody-Mediated Rejection in Renal Transplant Recipients.

about

P2860

P2860

Review of the Clinical and Economic Burden of Antibody-Mediated Rejection in Renal Transplant Recipients.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P407

P433

P478

P50

P577

P6179

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P407

P433

P478

P50

P577

P6179

P698